Acute myelocytic leukemia (AML) is a malignant neoplasm of hematopoietic cells
characterized by an abnormal proliferation of myeloid precursor cells, decreased rate of self …

Many new insights into the diagnosis, pathogenesis, clinical manifestation, treatment and
prognosis of patients with AML reflect the heterogeneity of the disease. The initial …

Acute myeloid leukaemia (AML) is a disorder characterized by a clonal proliferation derived
from primitive haematopoietic stem cells or progenitor cells. Abnormal differentiation of …

BACKGROUND AND OBJECTIVE: The successful use of differentiating treatment for
patients with acute promyelocytic leukemia (APL) suggests that other acute myeloid …

Acute myeloid leukemia (AML) is a genetically heterogeneous clonal disorder characterized
by the accumulation of acquired somatic genetic alterations in hematopoietic progenitor …

Understanding genomic events and the cascade of their effects in cell function is crucial for
identifying distinct subsets of acute myeloid leukemia and developing new therapeutic …

Acute leukemia is a worldwide disease with an incidence of approximately 4/100 000 per
year; 70% of the cases are acute myeloid leukemia (AML). The salient pathologic feature of …

Acute myeloid leukemia (AML) is the most frequently diagnosed acute leukemia, and its
incidence increases with age. Although the etiology of AML remains unknown, exposure to …

Acute myeloid leukemia (AML) is a biologically complex and molecularly and clinically
heterogeneous disease, and its incidence is increasing as the population ages …

The therapeutic approach to the patient with acute myeloid leukemia (AML) currently
evolves toward new frontiers. This is particularly apparent from the entree of high-throughput …